Current evidence for the use of sugammadex in children

Paediatric Anaesthesia

Volumn 27, Issue 2, 2017, Pages 118-125

  Tobias, Joseph D ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

neostigmine; neuromuscular blockade; sugammadex; train of four monitoring

Indexed keywords

DEXAMETHASONE; FENTANYL; GLYCOPYRRONIUM; NEOSTIGMINE; PLACEBO; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUGAMMADEX; VECURONIUM; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; ANESTHESIA INDUCTION; DRUG CLEARANCE; DRUG PENETRATION; DRUG POTENTIATION; DUCHENNE MUSCULAR DYSTROPHY; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; MANUAL EMERGENCY VENTILATOR; MUSCLE TONE; MYASTHENIA GRAVIS; MYOTONIC DYSTROPHY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; OXYGEN SATURATION; PEDIATRIC ANESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CHILD; INFANT; PRESCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; GAMMA-CYCLODEXTRINS; HUMANS; INFANT; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 85006007441     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.13050     Document Type: Review

References (46)

1. de Souza CM, Romero FE, Tardelli MA. Assessment of neuromuscular blockade in children at the time of block reversal and the removal of the endotracheal tube. Rev Bras Anestesiol 2011; 61: 145–149.
2. Meretoja OA. Neuromuscular block and current treatment strategies for its reversal in children. Pediatr Anesth 2010; 20: 591–604.
3. Murphy GS, Szokol JW, Marymont JH et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107: 130–137.
4. Shorten GD. Postoperative residual curarisation: incidence, aetiology and associated morbidity. Anaesth Intensive Care 1993; 21: 782–789.
5. Eriksson LI. The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Anesth Analg 1999; 89: 243–251.
6. Ghoneim AA, El Beltagy MA. Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients. Saudi J Anaesth 2015; 9: 247–252.
7. Eikermann M, Zaremba S, Malhotra A et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101: 344–349.
8. Bom A, Hope F, Rutherford S et al. Preclinical pharmacology of sugammadex. J Crit Care 2009; 24: 29–35.
9. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006; 97: 123–126.
10. Cammu G, De Kam PJ, Demeyer I et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008; 100: 373–379.
11. Gijsenbergh F, Ramael S, Houwing N et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695–703.
12. Sorgenfrei IF, Norrild K, Larsen PB et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667–674.
13. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575–581.
14. Chambers D, Paulden M, Paton F et al. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth 2010; 105: 568–575.
15. Lee C, Jahr JS, Candiotti KA et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009; 110: 1020–1025.
16. Barbosa FT, da Cunha RM. Reversal of profound neuromuscular blockade with sugammadex after failure of rapid sequence endotracheal intubation: a case report. Rev Bras Anestesiol 2012; 62: 281–284.
17. Wołoszczuk-Gębicka B, Zawadzka-Głos L, Lenarczyk J et al. Two cases of the “cannot ventilate, cannot intubate” scenario in children in view of recent recommendations. Anaesthesiol Intensive Ther 2014; 46: 88–91.
18. Yang LPH, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs 2009; 69: 919–942.
19. Duvaldestin P, Plaud B. Sugammadex in anesthesia practice. Expert Opin Pharmacother 2010; 11: 2759–2771.
20. Plaud B, Meretoja O, Hofmockel R et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009; 110: 284–294.
21. Gulec E, Biricik E, Turktan M et al. The effect of intravenous dexamethasone on sugammadex reversal time in children undergoing adenotonsillectomy. Anesth Analg 2016; 122: 1147–1152.
22. Ozgün C, Cakan T, Baltacı B et al. Comparison of reversal and adverse effects of sugammadex and combination of anticholinergic-anticholinesterase agents in pediatric patients. J Res Med Sci 2014; 19: 762–768.
23. Kara T, Ozbagriacik O, Turk HS et al. Sugammadex versus neostigmine in pediatric patients: a prospective randomized study. Rev Bras Anestesiol 2014; 64: 400–405.
24. Matinyan NV, Saltanov AI, Mareeva AA. Sugammadex use experience in pediatric oncology. Anesteziol Reanimatol 2013; 8: 34–37.
25. Martin DP, Crawford J, Uffman J et al. Sugammadex and fast-track anesthesia for pediatric cardiac surgery in a developing country. Anaesth Pain Intensive Care (in press).
26. de Boer HD, van Esmond J, Booij LH et al. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy. Pediatr Anesth 2009; 19: 1226–1228.
27. Takeda A, Kawamura M, Hamaya I et al. Case of anesthesia for thoracoscopic thymectomy in a pediatric patient with myasthenia gravis: reversal of rocuronium-induced neuromuscular blockade with sugammadex. Masui 2012; 61: 855–858.
28. Pickard A, Lobo C, Stoddart PA. The effect of rocuronium and sugammadex on neuromuscular blockade in a child with congenital myotonic dystrophy type 1. Pediatr Anesth 2013; 23: 871–873.
29. Stewart PA, Phillips S, De Boer HD. Sugammadex reversal of rocuronium-induced neuromuscular blockade in two types of neuromuscular disorders: myotonic dystrophy and spinal muscular atrophy. Rev Esp Anestesiol Reanim 2013; 60: 226–229.
30. Witte W, Nobel C, Hilpert J. Anesthesia and Angelman syndrome. Anaesthesist 2011; 60: 633–640.
31. Carlos RV, Torres ML, de Boer HD. The use of rocuronium and sugammadex in paediatric renal transplantation: two case reports. Eur J Anaesthesiol 2015; 32: 1–4.
32. Gomez-Rios MA, Lopez LR. Use of combination of rocuronium and sugammadex in heart transplant recipients. Anaesth Intensive Care 2012; 40: 903–904.
33. Peeters P, Passier P, Smeets J et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos 2011; 32: 159–167.
34. Carlos RV, Torres ML, de Boer HD. Rocuronium and sugammadex in a 3 day old neonate for draining an ovarian cyst. Neuromuscular management and review of the literature. Braz J Anesthesiol 2016; 66: 430–432.
35. Cardenas VHG, Gonzalez FDM. Sugammadex in the neonatal patient. Rev Colomb Anesthesiol 2013; 41: 171–174.
36. Langley RJ, McFadzean J, McCormack J. The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex. Pediatr Anesth 2016; 26: 109–111.
37. Alonso A, de Boer HD, Booij L. Reversal of rocuronium-induced neuromuscular block by sugammadex in neonates. Eur J Anaesthesiol 2014; 31(Suppl 52): 163–165.
38. Black AE, Flynn PE, Smith HL et al. Association of Pediatric Anaesthetists of Great Britain and Ireland Development of a guideline for the management of the unanticipated difficult airway in pediatric practice. Pediatr Anesth 2015; 25: 346–362.
39. Rahe-Meyer N, Fennema H, Schulman S et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology 2014; 121: 969–977.
40. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia 2014; 69: 1251–1257.
41. Schmidt AR, Weiss M, Engelhardt T. The paediatric airway: basic principles and current developments. Eur J Anaesthesiol 2014; 31: 293–299.
42. Shimizu T, Toda Y, Shimizu K et al. Increase in serum vecuronium concentration following sugammadex administration in a pediatric patient after prolonged sedation. Masui 2013; 62: 1225–1229.
43. Iwasaki H, Takahoko K, Otomo S et al. A temporary decrease in twitch response following reversal of rocuronium-induced neuromuscular block with a small dose of sugammadex in a pediatric patient. J Anesth 2014; 28: 288–290.
44. de Boer HD, Driessen JJ, van Egmond J et al. Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Can J Anaesth 2008; 55: 124–125.
45. Asakura C, Iwasaki H. The use of succinylcholine after sugammadex reversal. J Anesth 2016; 30: 915.
46. Nishi M, Fujii S, Nitta S. A two-year-old patient who received readministration of rocuronium for re-operation 30 minutes after sugammadex reversal. Masui 2011; 60: 1189–1191.